Parkinson's disease Parkinson's disease
Conditions
Interventions
Equfina 50mg tablet) will be taken orally once a day after breakfast for 24 weeks.
D008996
MAO-B inhibitors
Sponsors
Ono Kenjiro
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Men and women aged 50 years or older on the date of consent 2) Patients with Parkinson's disease 3) Patients who receives treatments with levodopa 4) Patients with wearing-off 5) MoCA-J score of 20 to 25 points 6) Patients who have undergone amyloid-beta pathology confirmation within the past 3 years or are willing to test for amyloid-beta pathology confirmation for this study. 7) Patients who does not receive treatments for cognitive decline, nor are not willing to start new treatment for cognitive decline. 8) Patinets who does not have intension to change anti-Parkinson's drugs other than adding Equfina 9) Patients who have a study partner. 10) Patients who have obtained written informed consent to participation of this study.
Exclusion criteria
Exclusion criteria: 1) Patients currently using MAO-B inhibitors 2) Patients currently participating in other clinical trials 3) Patients who are unsuitable for research participants judged by the Principal Investigator or Co-Investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome is change in cognitive performance from baseline to 24 weeks. Cognition is assessed using the MoCA-J score. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcomes are changes in motor and non-motor symptoms of Parkinson's disease; changes in cognitive performance, and changes in blood biomarkers from baseline to 24 weeks. | — |
Contacts
Public ContactMoeko Shinohara
Kanazawa University Hospital
Outcome results
None listed